The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes

BackgroundThe programmed cell death ligand 1 (PD-L1) plays a key role in glioma development. However, due to the specificity of glioma’s anatomical position, the role of its expression as a tumor biomarker is limited. It has been proven that the levels of soluble programmed death-ligand 1 (sPD-L1) a...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Xing-Chen Ding, Liang-Liang Wang, Yu-Fang Zhu, Yan-Dong Li, Shu-Lun Nie, Jia Yang, Hua Liang, Ralph R. Weichselbaum, Jin-Ming Yu, Man Hu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-10-01
Subjects:	soluble programmed cell death-ligand 1 glioma radiotherapy clinical significance prognosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.580335/full